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A 57-year-old female patient was treated with metronida-
zole due to paralytic ileus. Two weeks later, she presented
with vertigo after being given a cumulative dose of 25 g. On
physical examination, she revealed gaze-induced bidirec-
tional nystagmus without other neurologic finding. Labo-
ratory findings, including white blood cell count and
cerebrospinal fluid (CSF) test, were all normal. Facial nerve
stimulation studies show decreased compound muscle ac-
tion potentials on both sides. Blink reflex studies, auditory
brainstem response, and pure tone audiometry were within
normal limits. Videonystagmography and vestibular func-
tion revealed central vestibulopathy.
Brain magnetic resonance imaging (MRI) demonstrated
symmetric high signal intensity in dorsal medulla (Fig. 1A)
and inferior colliculus (Fig. 1B) on T2-weighted fluid-
attenuated inversion recovery imaging (T2WFLAIR). Her
vertigo resolved in 2 weeks after cessation of metronida-
zole. Follow-up of brain MRI showed no previous brain le-
sions (Fig. 1C and D).
Metronidazole, a 5-nitroimidazole compound, is a good
choice for treating anaerobic and protozoa-related in-
fections. However, in rare cases, it can adversely induce
peripheral neuropathy or encephalopathy [1] due to its
cellular penetration to CSF. Metronidazole-induced en-
cephalopathy (MIE) is one serious but rare side effect. The
exact mechanism of the neurotoxicity is yet to be clarified.
Rao and Mason [2] reported that catecholamine neuro-
transmitters can induce 5-nitroimidazole drugs to produce
semiquinone radicals and nitro anion radicals, which may
contribute to neural damage.
Graves et al.’s [3] study stated that MIE will occur if a
daily dose of 1.6 g is used for an average duration of
79 days. However, our patient received 1.5 g daily for
14 days, which was originally considered to be within the1607-551X/$36 Copyright ª 2013, Kaohsiung Medical University. Publish
http://dx.doi.org/10.1016/j.kjms.2013.08.001safety range. Most reported initial symptoms of MIE were
gait disturbance, dysarthria, altered consciousness, and
weakness of extremities. Vertigo, which presented as the
first symptom in our patient, is extremely rare. Because of
the occurrence of gaze-induced bidirectional nystagmus,
central vertigo was highly suspected. It indicated that the
lesion could be at brain stem, cerebellum, and brain
stemecerebellum axis [4]. Her vertigo could be explained
by lesions of medulla and inferior colliculus found on the
MRI study. Furthermore, her vertigo and MRI lesion
recovered soon after cessation of metronidazole intake.
The characteristic brain lesions of MIE can appear as
abnormal high signal intensity on diffusion-weighted im-
aging, T2W, and FLAIR MRI images. In descending order of
frequency, the previously reported lesions were at cere-
bellar dentate nuclei, midbrain, corpus callosum, pons,
medulla, cerebral white matter, and basal ganglia [5]. To
our knowledge, our patient’s lesions were present in both
dorsal medulla and inferior colliculus, meaning that these
were the first reported combination lesions of the central
nervous system.
The symptoms and signs of MIE can resolve completely
by an average of 37 days after termination of metronida-
zole usage, as reported in Graves et al.’s study [3]. Our
patient showed a good prognosis in 14 days. However, Kim
et al. described an irreversible MIE case. Special low
apparent diffusion coefficient lesions in MRI study may
indicate a poor prognosis. Groothoff et al. reported a fatal
case probably due to long exposure to a high dose of
metronidazole.
Vertigo is a commonly encountered complaint associated
with otolaryngologists and neurologists. Usually, to differ-
entiate between peripheral and central types is a chal-
lenge. Central vertigo due to MIE should be considered in
the differential diagnosis when central type of nystagmus
and a history of metronidazole usage are identified. Closeed by Elsevier Taiwan LLC. All rights reserved.
Figure 1. Fluid-attenuated inversion recovery magnetic resonance imaging revealed symmetric high signal intensity in both (A)
dorsal medulla (arrowheads) and (B) inferior colliculus (arrows). (C, arrowheads; D, arrows). The signal disappeared completely
after cessation of metronidazole.
696 Letter to the Editormonitoring of side effects during metronidazole usage,
even in the case of a safe dosage, is essential, and it must
be discontinued immediately after MIE is confirmed by
brain MRI.
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